As predictive factors for breast cancer, estrogen receptor (ER) modulators can predict the likelihood of response to hormone therapy, and HER2/neu can predict the value of monoclonal antibodies, such as trastuzumab, pertuzumab, and neratinib [9,10]. This evidence concerns the gene ERBB2 and breast carcinoma.